2A Pharma is a clinical stage biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on proprietary AAVLP platform technology. 2A Pharma’s vaccine platform is based on mutated parvoviral particles consisting essentially of one protein. The particles contain no viral genome and are replicative defective and non-pathogenic. Peptide sequences can be genetically inserted in two sites, allowing us to generate monovalent or bivalent vaccines as required. The pipeline consists of seven vaccine candidates that are being developed in-house or in collaboration with partners.
- Bli medlem
- Om SwedenBIO